269 related articles for article (PubMed ID: 35503983)
1. The Evolving Treatment Landscape in
Tabernero J; Ros J; Élez E
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35503983
[TBL] [Abstract][Full Text] [Related]
2. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR
Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK
Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847
[TBL] [Abstract][Full Text] [Related]
3. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
4. Retrospective Analysis of Treatment Pathways in Patients With BRAF
Gerger A; Eisterer W; Fuxius S; Bastian S; Koeberle D; Welslau M; Sanoyan DA; Maas C; Uhlig J; Fenchel K; Greil R; VON DER Heyde E; Agocs GR; Weide R; Schwager M; Reichenbach F; Modest DP; Fritsch R
Anticancer Res; 2022 Oct; 42(10):4773-4785. PubMed ID: 36191968
[TBL] [Abstract][Full Text] [Related]
5. Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
Shahjehan F; Kamatham S; Chandrasekharan C; Kasi PM
Drugs Today (Barc); 2019 Nov; 55(11):683-693. PubMed ID: 31840683
[TBL] [Abstract][Full Text] [Related]
6. [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version].
Hummel M; Hegewisch-Becker S; Neumann J; Vogel A
Pathologe; 2021 Nov; 42(6):578-590. PubMed ID: 33956173
[TBL] [Abstract][Full Text] [Related]
7. Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report.
Gallois C; Taieb J; Sabouret A; Broudin C; Karoui M; Garinet S; Zaanan A
Genes Chromosomes Cancer; 2022 Feb; 61(2):114-118. PubMed ID: 34773327
[TBL] [Abstract][Full Text] [Related]
8. BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer.
Kotani D; Bando H; Taniguchi H; Masuishi T; Komatsu Y; Yamaguchi K; Nakajima T; Satoh T; Nishina T; Esaki T; Nomura S; Takahashi K; Iida S; Matsuda S; Motonaga S; Fuse N; Sato A; Fujii S; Ohtsu A; Ebi H; Yoshino T
ESMO Open; 2020; 5(1):e000624. PubMed ID: 33551068
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
Eriksen M; Pfeiffer P; Rohrberg KS; Yde CW; Petersen LN; Poulsen LØ; Qvortrup C
BMC Cancer; 2022 Dec; 22(1):1321. PubMed ID: 36527039
[TBL] [Abstract][Full Text] [Related]
10. BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options.
Hummel M; Hegewisch-Becker S; Neumann JHL; Vogel A
Pathologe; 2021 Nov; 42(Suppl 1):98-109. PubMed ID: 34259881
[TBL] [Abstract][Full Text] [Related]
11. The BEETS (JACCRO CC-18) trial: an observational and translational study of
Inagaki C; Matoba R; Yuki S; Shiozawa M; Tsuji A; Inoue E; Muro K; Ichikawa W; Fujii M; Sunakawa Y
Future Oncol; 2023 Jun; 19(17):1165-1174. PubMed ID: 37458152
[TBL] [Abstract][Full Text] [Related]
12. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
Grothey A; Fakih M; Tabernero J
Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
[TBL] [Abstract][Full Text] [Related]
13. Treatment of
Ros J; Rodríguez-Castells M; Saoudi N; Baraibar I; Salva F; Tabernero J; Élez E
Expert Rev Anticancer Ther; 2023; 23(8):797-806. PubMed ID: 37482749
[TBL] [Abstract][Full Text] [Related]
14. Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.
Hafliger E; Boccaccino A; Lapeyre-Prost A; Perret A; Gallois C; Antista M; Pilla L; Lecomte T; Scartozzi M; Soularue E; Salvatore L; Bourgeois V; Salati M; Tougeron D; Evesque L; Vaillant JN; El-Khoury R; Lonardi S; Cremolini C; Taieb J
Eur J Cancer; 2022 Jun; 168():34-40. PubMed ID: 35436675
[TBL] [Abstract][Full Text] [Related]
15. Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation.
Al-Salama ZT
Drugs; 2021 May; 81(7):849-856. PubMed ID: 33914242
[TBL] [Abstract][Full Text] [Related]
16. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic
van Geel RMJM; Tabernero J; Elez E; Bendell JC; Spreafico A; Schuler M; Yoshino T; Delord JP; Yamada Y; Lolkema MP; Faris JE; Eskens FALM; Sharma S; Yaeger R; Lenz HJ; Wainberg ZA; Avsar E; Chatterjee A; Jaeger S; Tan E; Maharry K; Demuth T; Schellens JHM
Cancer Discov; 2017 Jun; 7(6):610-619. PubMed ID: 28363909
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF
García-Alfonso P; Lièvre A; Loupakis F; Tadmouri A; Khan S; Barcena L; Stintzing S
Crit Rev Oncol Hematol; 2022 May; 173():103646. PubMed ID: 35344913
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF
Kotani D; Takashima A; Kato T; Satoh T; Masuishi T; Komatsu Y; Shiozawa M; Esaki T; Izawa N; Takeuchi S; Bando H; Iwasa S; Hasegawa H; Yamaguchi T; Taniguchi H; Ushida Y; Oizaki T; Inoue C; Yoshino T
Clin Colorectal Cancer; 2024 Jun; 23(2):174-182.e6. PubMed ID: 38553360
[TBL] [Abstract][Full Text] [Related]
19. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With
Van Cutsem E; Huijberts S; Grothey A; Yaeger R; Cuyle PJ; Elez E; Fakih M; Montagut C; Peeters M; Yoshino T; Wasan H; Desai J; Ciardiello F; Gollerkeri A; Christy-Bittel J; Maharry K; Sandor V; Schellens JHM; Kopetz S; Tabernero J
J Clin Oncol; 2019 Jun; 37(17):1460-1469. PubMed ID: 30892987
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapy for Colorectal Cancer.
Sakata S; Larson DW
Surg Oncol Clin N Am; 2022 Apr; 31(2):255-264. PubMed ID: 35351276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
